RU2472784C2 - Бициклосульфониловая кислота (bcsa) и ее применение в качестве терапевтических агентов - Google Patents
Бициклосульфониловая кислота (bcsa) и ее применение в качестве терапевтических агентов Download PDFInfo
- Publication number
- RU2472784C2 RU2472784C2 RU2009145296/04A RU2009145296A RU2472784C2 RU 2472784 C2 RU2472784 C2 RU 2472784C2 RU 2009145296/04 A RU2009145296/04 A RU 2009145296/04A RU 2009145296 A RU2009145296 A RU 2009145296A RU 2472784 C2 RU2472784 C2 RU 2472784C2
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- independently
- nnn
- compound according
- optionally substituted
- Prior art date
Links
- 0 C*(C(*)=O)N*(C)O Chemical compound C*(C(*)=O)N*(C)O 0.000 description 10
- OBTMVAXZZGFZFH-UHFFFAOYSA-N CC(C#CC)Oc(cc1)ccc1N(C(CC(NO)=O)c1c2cccc1)S2(=O)=O Chemical compound CC(C#CC)Oc(cc1)ccc1N(C(CC(NO)=O)c1c2cccc1)S2(=O)=O OBTMVAXZZGFZFH-UHFFFAOYSA-N 0.000 description 2
- LPNWCCSAMLJEPX-UHFFFAOYSA-N ONC(CC(c1c2cccc1)N(c(cc1)ccc1-c1ccccc1)S2(=O)=O)=O Chemical compound ONC(CC(c1c2cccc1)N(c(cc1)ccc1-c1ccccc1)S2(=O)=O)=O LPNWCCSAMLJEPX-UHFFFAOYSA-N 0.000 description 2
- WIHHMUWVTLKSGB-UHFFFAOYSA-N ONC(CC(c1c2cccc1)N(c(cc1)ccc1N1CCOCC1)S2(=O)=O)=O Chemical compound ONC(CC(c1c2cccc1)N(c(cc1)ccc1N1CCOCC1)S2(=O)=O)=O WIHHMUWVTLKSGB-UHFFFAOYSA-N 0.000 description 2
- PXMCKHLMIAMZKH-UHFFFAOYSA-N ONC(CC(c1ccccc11)N(c(cc2)ccc2OCc2cccnc2)S1(=O)=O)=O Chemical compound ONC(CC(c1ccccc11)N(c(cc2)ccc2OCc2cccnc2)S1(=O)=O)=O PXMCKHLMIAMZKH-UHFFFAOYSA-N 0.000 description 2
- VXDBMUFGJXGKLF-UHFFFAOYSA-N CC(C)(C)OC(NCC#CCOc(cc1)ccc1N)=O Chemical compound CC(C)(C)OC(NCC#CCOc(cc1)ccc1N)=O VXDBMUFGJXGKLF-UHFFFAOYSA-N 0.000 description 1
- UWDVKPOIZZFXFP-UHFFFAOYSA-N CCOc(cc1C(CC(NO)=O)N2c3ccccc3)ccc1S2(=O)=O Chemical compound CCOc(cc1C(CC(NO)=O)N2c3ccccc3)ccc1S2(=O)=O UWDVKPOIZZFXFP-UHFFFAOYSA-N 0.000 description 1
- GQHCTBHNJCZKTI-UHFFFAOYSA-N CN(C(CC(NO)=O)c1c2cccc1)S2(=O)=O Chemical compound CN(C(CC(NO)=O)c1c2cccc1)S2(=O)=O GQHCTBHNJCZKTI-UHFFFAOYSA-N 0.000 description 1
- MUJFRALRRRGJGO-UHFFFAOYSA-N CN(C)C(Sc1c(C=O)cccc1)=O Chemical compound CN(C)C(Sc1c(C=O)cccc1)=O MUJFRALRRRGJGO-UHFFFAOYSA-N 0.000 description 1
- UFTGBWOETMSHQP-SNAWJCMRSA-N COC(/C=C/c(cc(c(OC)c1)OC)c1S(Cl)(=O)=O)=O Chemical compound COC(/C=C/c(cc(c(OC)c1)OC)c1S(Cl)(=O)=O)=O UFTGBWOETMSHQP-SNAWJCMRSA-N 0.000 description 1
- BDQBGUYSONYRBT-CSKARUKUSA-N COC(/C=C/c(ccc(Br)c1)c1S(Nc1ccccc1)(=O)=O)=O Chemical compound COC(/C=C/c(ccc(Br)c1)c1S(Nc1ccccc1)(=O)=O)=O BDQBGUYSONYRBT-CSKARUKUSA-N 0.000 description 1
- SLNNBAPOZFYBGV-UHFFFAOYSA-N COC(CC(c1c2cccc1)N(c(cc1)ccc1-[n]1cncc1)S2(=O)=O)=O Chemical compound COC(CC(c1c2cccc1)N(c(cc1)ccc1-[n]1cncc1)S2(=O)=O)=O SLNNBAPOZFYBGV-UHFFFAOYSA-N 0.000 description 1
- NINMFUJECVXBGM-UHFFFAOYSA-N COC(CC(c1c2cccc1Cl)N(c1ccccc1)S2(=O)=O)=O Chemical compound COC(CC(c1c2cccc1Cl)N(c1ccccc1)S2(=O)=O)=O NINMFUJECVXBGM-UHFFFAOYSA-N 0.000 description 1
- BTQKAAAALWTZTE-UHFFFAOYSA-N COC(CC(c1cccc(Cl)c11)N(c2ccccc2)S1(=O)=O)=O Chemical compound COC(CC(c1cccc(Cl)c11)N(c2ccccc2)S1(=O)=O)=O BTQKAAAALWTZTE-UHFFFAOYSA-N 0.000 description 1
- HJLHJYFPSMWQNS-UHFFFAOYSA-N COc(c(Cl)c1C(CC(NO)=O)N2c3ccccc3)ccc1S2(=O)=O Chemical compound COc(c(Cl)c1C(CC(NO)=O)N2c3ccccc3)ccc1S2(=O)=O HJLHJYFPSMWQNS-UHFFFAOYSA-N 0.000 description 1
- FMCZZYZWTRQLCK-UHFFFAOYSA-N COc(cc(C(CC(NO)=O)N(c1ccccc1)S1(=O)=O)c1c1)c1OC Chemical compound COc(cc(C(CC(NO)=O)N(c1ccccc1)S1(=O)=O)c1c1)c1OC FMCZZYZWTRQLCK-UHFFFAOYSA-N 0.000 description 1
- MEGPFIDAMVTPCT-UHFFFAOYSA-N COc(cc(cc1C(CC(NO)=O)N2c3ccccc3)Cl)c1S2(=O)=O Chemical compound COc(cc(cc1C(CC(NO)=O)N2c3ccccc3)Cl)c1S2(=O)=O MEGPFIDAMVTPCT-UHFFFAOYSA-N 0.000 description 1
- DHKQHBAYXKZBHD-UHFFFAOYSA-N COc(cc(cc1C(CC(O)=O)N2c3ccccc3)Cl)c1S2(=O)=O Chemical compound COc(cc(cc1C(CC(O)=O)N2c3ccccc3)Cl)c1S2(=O)=O DHKQHBAYXKZBHD-UHFFFAOYSA-N 0.000 description 1
- BNEDZZNHVLDTPU-UHFFFAOYSA-N COc(cc1C(CC(NO)=O)N2c3ccccc3)cc(OC)c1S2(=O)=O Chemical compound COc(cc1C(CC(NO)=O)N2c3ccccc3)cc(OC)c1S2(=O)=O BNEDZZNHVLDTPU-UHFFFAOYSA-N 0.000 description 1
- NQAMMEVJBPKACF-UHFFFAOYSA-N COc(cc1C(CC(O)=O)N2c3ccccc3)ccc1S2(=O)=O Chemical compound COc(cc1C(CC(O)=O)N2c3ccccc3)ccc1S2(=O)=O NQAMMEVJBPKACF-UHFFFAOYSA-N 0.000 description 1
- YKNCFDCWSWMCHW-UHFFFAOYSA-N COc(cccc1)c1N(C(CC(NO)=O)c1c2cccc1)S2(=O)=O Chemical compound COc(cccc1)c1N(C(CC(NO)=O)c1c2cccc1)S2(=O)=O YKNCFDCWSWMCHW-UHFFFAOYSA-N 0.000 description 1
- UIZGJFIEERLQCA-UHFFFAOYSA-N COc(nc1)ccc1N(C(CC(NO)=O)c1ccccc11)S1(=O)=O Chemical compound COc(nc1)ccc1N(C(CC(NO)=O)c1ccccc11)S1(=O)=O UIZGJFIEERLQCA-UHFFFAOYSA-N 0.000 description 1
- DQPDVULIRZLTPR-UHFFFAOYSA-N COc1cccc(N(C(CC(NO)=O)c2ccccc22)S2(=O)=O)c1 Chemical compound COc1cccc(N(C(CC(NO)=O)c2ccccc22)S2(=O)=O)c1 DQPDVULIRZLTPR-UHFFFAOYSA-N 0.000 description 1
- CVDZWSHZXODISZ-UHFFFAOYSA-N CSc(cc1)ccc1N(C(CC(NO)=O)c1c2cccc1)S2(=O)=O Chemical compound CSc(cc1)ccc1N(C(CC(NO)=O)c1c2cccc1)S2(=O)=O CVDZWSHZXODISZ-UHFFFAOYSA-N 0.000 description 1
- HHJGMXMMZDNOOO-UHFFFAOYSA-N Cc1cc(CCl)cc(C)n1 Chemical compound Cc1cc(CCl)cc(C)n1 HHJGMXMMZDNOOO-UHFFFAOYSA-N 0.000 description 1
- LROHZOKXBXOVSU-UHFFFAOYSA-N Cc1cc(S(N(C2CC(O)=O)c3ccccc3)(=O)=O)c2cc1 Chemical compound Cc1cc(S(N(C2CC(O)=O)c3ccccc3)(=O)=O)c2cc1 LROHZOKXBXOVSU-UHFFFAOYSA-N 0.000 description 1
- DRAPBUPJVXGEEG-UHFFFAOYSA-N Cc1cc(S(Nc2ccccc2)(=O)=O)ccc1 Chemical compound Cc1cc(S(Nc2ccccc2)(=O)=O)ccc1 DRAPBUPJVXGEEG-UHFFFAOYSA-N 0.000 description 1
- AZAJWPCKXUQPEU-UHFFFAOYSA-N Cc1nc(-c(cc2)ccc2N(C(CC(NO)=O)c2ccccc22)S2(=O)=O)c[s]1 Chemical compound Cc1nc(-c(cc2)ccc2N(C(CC(NO)=O)c2ccccc22)S2(=O)=O)c[s]1 AZAJWPCKXUQPEU-UHFFFAOYSA-N 0.000 description 1
- BLWJEYVPBIEKER-UHFFFAOYSA-N Cc1nc(C)cc(COc(cc2)ccc2N(C(CC(OC)=O)c2c3cccc2)S3(=O)=O)c1 Chemical compound Cc1nc(C)cc(COc(cc2)ccc2N(C(CC(OC)=O)c2c3cccc2)S3(=O)=O)c1 BLWJEYVPBIEKER-UHFFFAOYSA-N 0.000 description 1
- PNYAMFFUIRCVJJ-UHFFFAOYSA-N Cc1nccc(COc(cc2)ccc2N(C(CC(NO)=O)c2c3cccc2)S3(=O)=O)c1 Chemical compound Cc1nccc(COc(cc2)ccc2N(C(CC(NO)=O)c2c3cccc2)S3(=O)=O)c1 PNYAMFFUIRCVJJ-UHFFFAOYSA-N 0.000 description 1
- CNQCWYFDIQSALX-UHFFFAOYSA-N ClCc1cccnc1 Chemical compound ClCc1cccnc1 CNQCWYFDIQSALX-UHFFFAOYSA-N 0.000 description 1
- OLSKQWRLRYMCAO-UHFFFAOYSA-N ClCc1ccnc2c1cccc2 Chemical compound ClCc1ccnc2c1cccc2 OLSKQWRLRYMCAO-UHFFFAOYSA-N 0.000 description 1
- QPXWZKCMZXNBHK-UHFFFAOYSA-N N#Cc(cc1)ccc1N(C(CC(NO)=O)c1c2cccc1)S2(=O)=O Chemical compound N#Cc(cc1)ccc1N(C(CC(NO)=O)c1c2cccc1)S2(=O)=O QPXWZKCMZXNBHK-UHFFFAOYSA-N 0.000 description 1
- RDIJUYZSTXDQQT-UHFFFAOYSA-N OC(CC(c1c2cc3OCCOc3c1)N(c1ccccc1)S2(=O)=O)=O Chemical compound OC(CC(c1c2cc3OCCOc3c1)N(c1ccccc1)S2(=O)=O)=O RDIJUYZSTXDQQT-UHFFFAOYSA-N 0.000 description 1
- BDNHHVDXOYFICO-UHFFFAOYSA-N OC(CC(c1c2cccc1)N(c(cc1)ccc1-[n]1ncnc1)S2(=O)=O)=O Chemical compound OC(CC(c1c2cccc1)N(c(cc1)ccc1-[n]1ncnc1)S2(=O)=O)=O BDNHHVDXOYFICO-UHFFFAOYSA-N 0.000 description 1
- NLNYJWPVPMZVEQ-UHFFFAOYSA-N OC(CC(c1c2cccc1)N(c(cc1)ccc1-c1cnc[o]1)S2(=O)=O)=O Chemical compound OC(CC(c1c2cccc1)N(c(cc1)ccc1-c1cnc[o]1)S2(=O)=O)=O NLNYJWPVPMZVEQ-UHFFFAOYSA-N 0.000 description 1
- ZQQVFMOXSZHGMG-UHFFFAOYSA-N OC(CC(c1c2cccc1)N(c(cc1)ccc1Oc1ccccc1)S2(=O)=O)=O Chemical compound OC(CC(c1c2cccc1)N(c(cc1)ccc1Oc1ccccc1)S2(=O)=O)=O ZQQVFMOXSZHGMG-UHFFFAOYSA-N 0.000 description 1
- KJHZXJQHICPLBG-UHFFFAOYSA-N OCC#CCOc(cc1)ccc1N(C(CC(NO)=O)c1c2cccc1)S2(=O)=O Chemical compound OCC#CCOc(cc1)ccc1N(C(CC(NO)=O)c1c2cccc1)S2(=O)=O KJHZXJQHICPLBG-UHFFFAOYSA-N 0.000 description 1
- GCCHGBDYQCANJH-UHFFFAOYSA-N OCc1cccc(N(C(CC(NO)=O)c2c3cccc2)S3(=O)=O)c1 Chemical compound OCc1cccc(N(C(CC(NO)=O)c2c3cccc2)S3(=O)=O)c1 GCCHGBDYQCANJH-UHFFFAOYSA-N 0.000 description 1
- ZJWJSRDJDYFBLZ-UHFFFAOYSA-N ONC(C(c1c2cccc1Cl)N(c1ccccc1)S2(=O)=O)=O Chemical compound ONC(C(c1c2cccc1Cl)N(c1ccccc1)S2(=O)=O)=O ZJWJSRDJDYFBLZ-UHFFFAOYSA-N 0.000 description 1
- QPSKNRFPOUCEDR-UHFFFAOYSA-N ONC(CC(c(c(Cl)c1)c2cc1Cl)N(c1ccccc1)S2(=O)=O)=O Chemical compound ONC(CC(c(c(Cl)c1)c2cc1Cl)N(c1ccccc1)S2(=O)=O)=O QPSKNRFPOUCEDR-UHFFFAOYSA-N 0.000 description 1
- FRYQCRIYXLXYHA-UHFFFAOYSA-N ONC(CC(c(cc1)c2cc1-c1ccccc1)N(c1ccccc1)S2(=O)=O)=O Chemical compound ONC(CC(c(cc1)c2cc1-c1ccccc1)N(c1ccccc1)S2(=O)=O)=O FRYQCRIYXLXYHA-UHFFFAOYSA-N 0.000 description 1
- YSSVPXCEYOILAS-UHFFFAOYSA-N ONC(CC(c1c2c(Cl)ccc1)N(c1ccccc1)S2(=O)=O)=O Chemical compound ONC(CC(c1c2c(Cl)ccc1)N(c1ccccc1)S2(=O)=O)=O YSSVPXCEYOILAS-UHFFFAOYSA-N 0.000 description 1
- GWNFTEYKQDHRBD-UHFFFAOYSA-N ONC(CC(c1c2cccc1)N(c(cc1)ccc1-[n]1ncnc1)S2(=O)=O)=O Chemical compound ONC(CC(c1c2cccc1)N(c(cc1)ccc1-[n]1ncnc1)S2(=O)=O)=O GWNFTEYKQDHRBD-UHFFFAOYSA-N 0.000 description 1
- AEHKCLSKGTZVJN-UHFFFAOYSA-N ONC(CC(c1c2cccc1)N(c(cc1)ccc1OCc1ccncc1)S2(=O)=O)=O Chemical compound ONC(CC(c1c2cccc1)N(c(cc1)ccc1OCc1ccncc1)S2(=O)=O)=O AEHKCLSKGTZVJN-UHFFFAOYSA-N 0.000 description 1
- NTZJPCJVYFZRRO-UHFFFAOYSA-N ONC(CC(c1c2cccc1)N(c1cc3ccccc3cc1)S2(=O)=O)=O Chemical compound ONC(CC(c1c2cccc1)N(c1cc3ccccc3cc1)S2(=O)=O)=O NTZJPCJVYFZRRO-UHFFFAOYSA-N 0.000 description 1
- KEISLELVZCGPBZ-UHFFFAOYSA-N ONC(CC(c1c2cccc1)N(c1n[nH]cc1)S2(=O)=O)=O Chemical compound ONC(CC(c1c2cccc1)N(c1n[nH]cc1)S2(=O)=O)=O KEISLELVZCGPBZ-UHFFFAOYSA-N 0.000 description 1
- STUBZTRQLGNSJV-UHFFFAOYSA-N ONC(CC(c1ccccc11)N(c(cc2)ccc2-c2cnc[o]2)S1(=O)=O)=O Chemical compound ONC(CC(c1ccccc11)N(c(cc2)ccc2-c2cnc[o]2)S1(=O)=O)=O STUBZTRQLGNSJV-UHFFFAOYSA-N 0.000 description 1
- LAKLIQVFWYDKCW-UHFFFAOYSA-N ONC(CC(c1ccccc11)N(c(cc2)ccc2Cl)S1(=O)=O)=O Chemical compound ONC(CC(c1ccccc11)N(c(cc2)ccc2Cl)S1(=O)=O)=O LAKLIQVFWYDKCW-UHFFFAOYSA-N 0.000 description 1
- PIUHOPXGTUGBID-UHFFFAOYSA-N ONC(CC(c1ccccc11)N(c(cc2)ccc2OCc2ccccn2)S1(=O)=O)=O Chemical compound ONC(CC(c1ccccc11)N(c(cc2)ccc2OCc2ccccn2)S1(=O)=O)=O PIUHOPXGTUGBID-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92451807P | 2007-05-18 | 2007-05-18 | |
| US60/924,518 | 2007-05-18 | ||
| PCT/GB2008/001683 WO2008142376A1 (en) | 2007-05-18 | 2008-05-16 | Bicyclosulfonyl acid (bcsa) compounds and their use as therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009145296A RU2009145296A (ru) | 2011-06-27 |
| RU2472784C2 true RU2472784C2 (ru) | 2013-01-20 |
Family
ID=39740054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009145296/04A RU2472784C2 (ru) | 2007-05-18 | 2008-05-16 | Бициклосульфониловая кислота (bcsa) и ее применение в качестве терапевтических агентов |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100311741A1 (https=) |
| EP (1) | EP2155703A1 (https=) |
| JP (1) | JP2010527344A (https=) |
| KR (1) | KR20100020479A (https=) |
| AU (1) | AU2008252628A1 (https=) |
| BR (1) | BRPI0811651A2 (https=) |
| CA (1) | CA2687415A1 (https=) |
| MX (1) | MX2009012470A (https=) |
| RU (1) | RU2472784C2 (https=) |
| WO (1) | WO2008142376A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2406248B1 (en) * | 2009-03-11 | 2013-12-25 | Msd K.K. | Novel isoindolin-1-one derivative |
| GB2475359A (en) * | 2009-11-11 | 2011-05-18 | Biocopea Ltd | A compound for use in treating a fulminant respiratory disorder |
| DK2597084T3 (en) | 2010-07-08 | 2016-08-15 | Kaken Pharma Co Ltd | N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICINAL CONTAINING SAME |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| WO2015091428A1 (en) * | 2013-12-20 | 2015-06-25 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| CN110790758A (zh) * | 2018-08-01 | 2020-02-14 | 上海轶诺药业有限公司 | 一类具有免疫调节功能的含n杂环化合物的制备和应用 |
| EP3750878B1 (en) | 2019-06-14 | 2025-05-14 | Vivoryon Therapeutics N.V. | Heteroaromatic inhibitors of astacin proteinases |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0350163A2 (en) * | 1988-06-09 | 1990-01-10 | Beecham Group Plc | Renin inhibitory peptides |
| EP0375451A2 (en) * | 1988-12-23 | 1990-06-27 | Beecham Group Plc | Compounds having a renin-inhibiting activity |
| RU2078081C1 (ru) * | 1991-12-30 | 1997-04-27 | Стерлинг Уинтроп Инк. | 2-сахаринилметилгетероциклические карбоксилаты или кислотно-аддитивные соли этих соединений основного характера или основно-аддитивные соли этих соединений кислотного характера, и фармацевтическая композиция, ингибирующая активность протеолитических ферментов |
| WO1999024419A1 (en) * | 1997-11-12 | 1999-05-20 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| US6319912B1 (en) * | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
| CA2531515A1 (en) * | 2003-07-10 | 2005-02-03 | Neurogen Corporation | Aryl-substituted benzo[d]isothiazol-3-ylamine analogues as capsaicin receptor modulators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6288063B1 (en) * | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
| WO2002081447A1 (en) * | 2001-04-06 | 2002-10-17 | Daewoong Pharmaceutical Co., Ltd. | 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof |
| WO2003031431A1 (en) * | 2001-10-09 | 2003-04-17 | Bristol-Myers Squibb Company | Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
-
2008
- 2008-05-16 AU AU2008252628A patent/AU2008252628A1/en not_active Abandoned
- 2008-05-16 KR KR1020097026376A patent/KR20100020479A/ko not_active Withdrawn
- 2008-05-16 JP JP2010507977A patent/JP2010527344A/ja active Pending
- 2008-05-16 CA CA002687415A patent/CA2687415A1/en not_active Abandoned
- 2008-05-16 WO PCT/GB2008/001683 patent/WO2008142376A1/en not_active Ceased
- 2008-05-16 MX MX2009012470A patent/MX2009012470A/es not_active Application Discontinuation
- 2008-05-16 BR BRPI0811651-2A2A patent/BRPI0811651A2/pt not_active IP Right Cessation
- 2008-05-16 RU RU2009145296/04A patent/RU2472784C2/ru not_active IP Right Cessation
- 2008-05-16 US US12/599,855 patent/US20100311741A1/en not_active Abandoned
- 2008-05-16 EP EP08750615A patent/EP2155703A1/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0350163A2 (en) * | 1988-06-09 | 1990-01-10 | Beecham Group Plc | Renin inhibitory peptides |
| EP0375451A2 (en) * | 1988-12-23 | 1990-06-27 | Beecham Group Plc | Compounds having a renin-inhibiting activity |
| RU2078081C1 (ru) * | 1991-12-30 | 1997-04-27 | Стерлинг Уинтроп Инк. | 2-сахаринилметилгетероциклические карбоксилаты или кислотно-аддитивные соли этих соединений основного характера или основно-аддитивные соли этих соединений кислотного характера, и фармацевтическая композиция, ингибирующая активность протеолитических ферментов |
| WO1999024419A1 (en) * | 1997-11-12 | 1999-05-20 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| US6319912B1 (en) * | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
| CA2531515A1 (en) * | 2003-07-10 | 2005-02-03 | Neurogen Corporation | Aryl-substituted benzo[d]isothiazol-3-ylamine analogues as capsaicin receptor modulators |
Non-Patent Citations (2)
| Title |
|---|
| F.Sauter and G.Buyuk, "Synthese von [1] Benzothieno [2,3-c]pyrazol-Derivaten", Monatshefte fur Chermie, No. 105, p.550-557, 1974. * |
| F.Sauter and G.Buyuk, "Synthese von [1] Benzothieno [2,3-c]pyrazol-Derivaten", Monatshefte fur Chermie, № 105, p.550-557, 1974. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010527344A (ja) | 2010-08-12 |
| US20100311741A1 (en) | 2010-12-09 |
| MX2009012470A (es) | 2010-02-24 |
| WO2008142376A1 (en) | 2008-11-27 |
| AU2008252628A1 (en) | 2008-11-27 |
| EP2155703A1 (en) | 2010-02-24 |
| BRPI0811651A2 (pt) | 2014-11-11 |
| CA2687415A1 (en) | 2008-11-27 |
| RU2009145296A (ru) | 2011-06-27 |
| KR20100020479A (ko) | 2010-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2472784C2 (ru) | Бициклосульфониловая кислота (bcsa) и ее применение в качестве терапевтических агентов | |
| ES2302938T3 (es) | Derivados de indol como agonistas beta-2. | |
| JP3894949B2 (ja) | 抗アテローム性動脈硬化症ジアリール化合物 | |
| JP5820882B2 (ja) | キナーゼインヒビターとしてのキノリン及びキノキサリン誘導体 | |
| ES2289691T3 (es) | Derivados de sulfonamida para el tratamiento de enfermedades. | |
| JP2006520796A (ja) | ヒストンデアセチラーゼインヒビター | |
| HU228960B1 (hu) | Ftalazinon-származékok | |
| ES2324922T3 (es) | Derivados de tiazol que tienen actividad inhibidora de vap-1. | |
| JP2010522735A (ja) | 腫瘍成長阻害剤としてのテトラヒドロイソキノリン | |
| EP1786773A1 (en) | Isoindolin-1-one derivatives | |
| JPWO2005047286A1 (ja) | スピロ複素環化合物 | |
| JP2008524244A (ja) | 水酸化ステロイド脱水素酵素阻害剤 | |
| WO2007049771A1 (ja) | 塩基性基を含有する化合物およびその用途 | |
| JPH10510536A (ja) | ２−置換された１，２，５−チアジアゾリジン−３−オン１，１−ジオキシド及びそれらの組成物 | |
| JP2012107031A (ja) | マトリックスメタロプロテイナーゼの阻害剤 | |
| HUP9903797A2 (hu) | Benzofurán-karboxamidok és -szulfonamidok, alkalmazásuk gyógyszerkészítmények előállítására és ezek a gyógyszerkészítmények | |
| JP2009508872A (ja) | カルバゾール誘導体 | |
| JP2010527986A (ja) | スピロ環状キナゾリン誘導体およびｐｄｅ７阻害剤としてのその使用 | |
| SK74999A3 (en) | 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists | |
| JP2007506664A (ja) | マトリックスメタロプロテイナーゼの阻害剤 | |
| WO2007047431A2 (en) | Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors | |
| WO1999005095A1 (en) | Aminocycloalkane compounds | |
| JPH0377191B2 (https=) | ||
| JP2001525398A (ja) | 選択的β３アドレナリン作動性アゴニスト | |
| HRP980216A2 (en) | Therapeutic 1,2,3,4-tetrahydroisoquinolines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140517 |